...

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors (vol 23, pg 6400, 2017)

【24h】

Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors (vol 23, pg 6400, 2017)

机译：患有和不含DNA修复突变的患者的差异毒性：I阶段研究高级实体瘤中的卡铂和TALAZOPARIB（Vol 23，PG 6400,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2018年第4期|共1页
作者
Dhawan M. S.; Bartelink I. H.; Aggarwal R. R.; Leng J.; Zhang J. Z.; Pawlowska N.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors (vol 23, pg 6400, 2017) [J] . Dhawan M. S., Bartelink I. H., Aggarwal R. R., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第4期

机译：患有和不含DNA修复突变的患者的差异毒性：I阶段研究高级实体瘤中的卡铂和TALAZOPARIB（Vol 23，PG 6400,2017）
2. OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC) [J] . N.Yamamoto, Y.Ichinose, Y.Nishiwaki, European Journal of Cancer Supplements . 2009,第4期

机译：基于IPASS的日本患者（pts）子集中的循环游离DNA（cfDNA）进行的OP78 EGFR突变（IRESSA泛亚研究），这是一线吉非替尼（G）与卡铂/紫杉醇（C / P）的III期研究临床选择的晚期非小细胞肺癌（NSCLC）患者
3. P1.04-004 Phase I/Ib Study of Nivolumab and Veliparib in Advanced Solid Tumors and Lymphoma with and without Alterations in Selected DNA Repair Genes [J] . Y. Chae, W. Iams, S. Pai, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P1.04-004阶段I / IB研究Nivolumab和Veliparib在先进的实体肿瘤和淋巴瘤中，淋巴瘤，并且选择的DNA修复基因的改变
4. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
5. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors [O] . Mary E. R. O’Brien, Debashis Sarker, Jaishree Bhosle, -1

机译：一项评估晚期阿马替尼与卡铂或卡铂加紫杉醇联合治疗的I期研究
6. Correction: Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors [O] . 2018

机译：校正：患有和不含DNA修复突变的患者的差异毒性：I阶段研究高级实体肿瘤中的卡铂和塔罗唑啉

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号